The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Analysts at Leerink Partnrs boosted their Q4 2024 EPS estimates for Bristol-Myers Squibb in a report released on Sunday, ...

The new American College of Cardiology expert consensus includes a four-part staging system with a segment for “asymptomatic” ...

"Be Bio secures $92m for haemophilia B and hypophosphatasia treatments" was originally created and published by ...

The Trump administration had an opportunity to spark a resurgence in American innovation through intellectual property reform ...

Green, a former pharmacist and pharma ad copywriter whose resume includes such agencies as Grey Healthcare and KPR (since ...

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.

Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Explore some of the best blue-chip ETFs to buy for investors who want to sleep well at night (SWAN) during their retirement ...